McKesson Corp (MCK) stock
MCKNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3027% above fair value
$1084.43−7.24 (-0.66%)
Close on Nov 18, 2026Market cap $126.43BP/E 29.0Yield 0.29%
McKesson operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
McKesson's operating income for the twelve months ending Jun 30, 2026 was $6.50B, up 46.6% year over year. For fiscal 2026 it was $6.21B, up 40.5% from the year before. Over ten years it grew 5.8% a year on average. The highest annual figure on record is $7.12B in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $6.21B | +40.5% |
| FY2025 | Mar 31, 2025 | $4.42B | +13.1% |
| FY2024 | Mar 31, 2024 | $3.91B | -10.8% |
| FY2023 | Mar 31, 2023 | $4.38B | +115.0% |
| FY2022 | Mar 31, 2022 | $2.04B | – |
| FY2021 | Mar 31, 2021 | -$5.04B | -302.5% |
| FY2020 | Mar 31, 2020 | $2.49B | +180.9% |
| FY2019 | Mar 31, 2019 | $886.00M | +16.3% |
| FY2018 | Mar 31, 2018 | $762.00M | -89.3% |
| FY2017 | Mar 31, 2017 | $7.12B | +100.9% |
| FY2016 | Mar 31, 2016 | $3.55B | +19.4% |
| FY2015 | Mar 31, 2015 | $2.97B | +21.7% |
| FY2014 | Mar 31, 2014 | $2.44B | +3.9% |
| FY2013 | Mar 31, 2013 | $2.35B | +10.5% |
| FY2012 | Mar 31, 2012 | $2.12B | +16.6% |
| FY2011 | Mar 31, 2011 | $1.82B | -9.3% |
| FY2010 | Mar 31, 2010 | $2.01B | +67.9% |
| FY2009 | Mar 31, 2009 | $1.20B | -19.1% |
| FY2008 | Mar 31, 2008 | $1.48B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $1.32B | +27.3% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $2.15B | +35.1% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $1.62B | +32.3% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $1.41B | +143.4% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $1.04B | +0.7% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $1.59B | +30.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $1.22B | +90.7% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $578.00M | -39.2% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $1.03B | -6.5% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $1.22B | +24.1% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $642.00M | -48.3% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $951.00M | -15.4% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $1.10B | +6.2% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $980.00M | +54.8% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $1.24B | +316.4% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $1.12B | +108.5% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $1.04B | +82.4% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $633.00M | -37.3% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $298.00M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $539.00M | -15.0% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $568.00M | -16.2% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $1.01B | +16.2% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$7.36B | -2145.0% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $634.00M | +1.3% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $678.00M | +6.9% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $869.00M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $360.00M | -47.3% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $626.00M | -9.1% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $634.00M | +663.9% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$569.00M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $683.00M | -18.1% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $689.00M | +188.3% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $83.00M | -86.9% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$944.00M | -119.9% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $834.00M | +0.4% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $239.00M | -58.8% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $633.00M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $4.74B | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $831.00M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $580.00M | – |
See a number that looks wrong?